Gilead Sciences has announced that the price it will charge U.S. insurers for remdesivir, its antiviral treatment for COVID-19 patients, is $520 per vial and $3,120 for a six-vial, five-day course of treatment.

However, the California drugmaker said the governments of developed countries, including the U.S., will pay $390 per vial and $2,340 for a six-vial, five-day course of treatment.

Gilead also announced that HHS will continue to manage distribution of remdesivir until the end of September.